Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

2.

Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.

Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F.

Mol Pharmacol. 2004 Jan;65(1):56-67.

3.

The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice.

Ren K, King MA, Liu J, Siemann J, Altman M, Meyers C, Hughes JA, Meyer EM.

Neuroscience. 2007 Aug 10;148(1):230-7.

PMID:
17640819
4.

3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.

Suzuki S, Kawamata J, Matsushita T, Matsumura A, Hisahara S, Takata K, Kitamura Y, Kem W, Shimohama S.

J Neurosci Res. 2013 Mar;91(3):462-71. doi: 10.1002/jnr.23160.

PMID:
23239187
5.

Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors.

Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL.

J Pharmacol Exp Ther. 1998 Dec;287(3):918-25.

6.
7.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
8.

Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity.

Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A.

Ann Neurol. 1997 Aug;42(2):159-63.

PMID:
9266724
9.
10.

alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats.

Chen L, Yamada K, Nabeshima T, Sokabe M.

Neuropharmacology. 2006 Feb;50(2):254-68.

PMID:
16324726
11.

Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors.

Kem WR, Mahnir VM, Papke RL, Lingle CJ.

J Pharmacol Exp Ther. 1997 Dec;283(3):979-92.

12.

Effects at a distance in alpha 7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy.

Papke RL, Meyer EM, Lavieri S, Bollampally SR, Papke TA, Horenstein NA, Itoh Y, Porter Papke JK.

Neuropharmacology. 2004 Jun;46(7):1023-38.

PMID:
15081799
13.

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.

Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.

J Pharmacol Exp Ther. 2009 May;329(2):459-68. doi: 10.1124/jpet.108.150094.

14.

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213.

16.

GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue.

van Haaren F, Anderson KG, Haworth SC, Kem WR.

Pharmacol Biochem Behav. 1999 Oct;64(2):439-44.

PMID:
10515327
17.

Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor.

Machu TK, Hamilton ME, Frye TF, Shanklin CL, Harris MC, Sun H, Tenner TE Jr, Soti FS, Kem WR.

J Pharmacol Exp Ther. 2001 Dec;299(3):1112-9.

18.

Septal innervation regulates the function of alpha7 nicotinic receptors in CA1 hippocampal interneurons.

Thinschmidt JS, Frazier CJ, King MA, Meyer EM, Papke RL.

Exp Neurol. 2005 Oct;195(2):342-52.

PMID:
16000197
19.

Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.

Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR.

Brain Res. 2010 Sep 17;1352:140-6. doi: 10.1016/j.brainres.2010.06.063.

20.

The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors.

Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL.

Mol Pharmacol. 2004 Jul;66(1):14-24.

Items per page

Supplemental Content

Support Center